Rapt Therapeutics (NASDAQ:RAPT – Get Free Report) and Solid Biosciences (NASDAQ:SLDB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.
Profitability
This table compares Rapt Therapeutics and Solid Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapt Therapeutics | N/A | -61.81% | -54.73% |
| Solid Biosciences | N/A | -71.54% | -58.27% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Rapt Therapeutics and Solid Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapt Therapeutics | 1 | 10 | 1 | 1 | 2.15 |
| Solid Biosciences | 1 | 0 | 10 | 0 | 2.82 |
Valuation and Earnings
This table compares Rapt Therapeutics and Solid Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapt Therapeutics | N/A | N/A | -$129.87 million | ($11.06) | -5.22 |
| Solid Biosciences | N/A | N/A | -$124.70 million | ($2.49) | -2.57 |
Rapt Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
99.1% of Rapt Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 2.4% of Rapt Therapeutics shares are owned by insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Rapt Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500.
Summary
Solid Biosciences beats Rapt Therapeutics on 7 of the 12 factors compared between the two stocks.
About Rapt Therapeutics
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
About Solid Biosciences
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Receive News & Ratings for Rapt Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapt Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
